Identification of Epinastine as CD96/PVR inhibitor for cancer immunotherapy
Our results demonstrated that the development of small molecule inhibitor Epinastine targeting CD96/PVR pathway, which proposed a promising strategy and drug candidate for cancer immunotherapy.
Authors
- Bing Zhai (ORCID: https://orcid.org/0000-0001-6571-7465)
- Lihan Zhang (ORCID: https://orcid.org/0000-0003-4364-6242)
- Yahong Wu
- Xiuman Zhou (ORCID: https://orcid.org/0000-0002-5938-450X)
- Xiaowen Zhou (ORCID: https://orcid.org/0000-0001-6401-1743)
- Qingchao Wang (ORCID: https://orcid.org/0000-0002-5373-9621)
- Ranran Shi (ORCID: https://orcid.org/0000-0002-8352-0452)
- Wen‐Hui Shen (ORCID: https://orcid.org/0000-0001-7988-6382)
- Xiangrui Zhang (ORCID: https://orcid.org/0000-0002-8743-8552)
- Wenshan Zhao (ORCID: https://orcid.org/0000-0002-8018-5978)
- Xiaoshuang Niu
- Beibei Li (ORCID: https://orcid.org/0000-0002-0485-1975)
- Peixin Chen (ORCID: https://orcid.org/0000-0002-4192-8396)
Institutions
- Sun Yat-sen University (CN)
- Zhengzhou University (CN)
- Luohe Medical College (CN)
- Henan Cancer Hospital (CN)
Publication Details
- Journal
- BMC Biology
- Published
- 2025-01-27
- DOI
- https://doi.org/10.1186/s12915-025-02132-y
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Zhengzhou University
- Natural Science Foundation of Henan Province
- Henan Provincial Science and Technology Research Project